Manuscript no. HAEMATOL/2012/073510 entitled “Cost-analysis of treatment of childhood acute lymphoblastic leukemia with asparaginase preparations: the impact of expensive chemotherapy”

Authors: Wing H. Tong, Inge M. van der Sluis, Cathelijne Alleman, Raphaële R.L. van Litsenburg, Gjl Kaspers, Rob Pieters, and Carin A. Uyl-de Groot

Information about the contributions of each person named as having participated in the study

1) Guarantor(s), i.e., person(s) who is (are) responsible for the integrity of the work as a whole:
   • Inge M. van der Sluis, Pediatric Oncology, i.vandersluis@erasusmc.nl
   • Rob Pieters, Pediatric Oncology, rob.pieters@erasusmc.nl

According to the International Committee of Medical Journal Editors (ICMJE) (http://www.icmje.org/ethical_1author.html): “Authorship credit should be based on: 1) substantial contributions to conception and design, acquisition of data, or analysis and interpretation of data; 2) drafting the article or revising it critically for important intellectual content; and 3) final approval of the version to be published. Authors should meet conditions 1, 2, and 3 …………………… Acquisition of funding, collection of data, or general supervision of the research group alone does not constitute authorship”.

The guarantors of this manuscript confirm that all persons designated as authors qualify for authorship, and that each author has participated sufficiently in the work to take public responsibility for appropriate portions of the content.

2) Authors who participated in the conception of the study: Inge M. van der Sluis, Rob Pieters and Carin A. Uyl-de Groot

3) Design & Methods. The following authors were responsible for specific investigations:
   • Inge M. van der Sluis, Rob Pieters and Carin A. Uyl-de Groot were responsible for the design of this study
   • Wing H. Tong was responsible for the design of this study and collecting clinical data, studying costs of asparaginase, and performance of statistics
   • Cathelijne J.M. Alleman was responsible for collecting clinical data, studying costs of asparaginase, performance of decision tree, sensitivity analyses, and statistics
   • Raphaële R.L. van Litsenburg and Gertjan J.L Kaspers provided clinical data, and performance of statistics

4) Results. The following authors were responsible for specific portions of the results, including figures and tables:
   • Wing H. Tong, Inge M. van der Sluis, Rob Pieters and Carin A. Uyl-de Groot were responsible for the calculation of costs of asparaginase per scenario and relating these costs to clinical data, the flowchart of three distinct scenarios of asparaginase treatment, decision tree and sensitivity analyses (Table 1-3, Figure 1-4)
   • Rob Pieters was responsible for the scheme of the intensification/continuation phase of the ALL-10 MR protocol as chair of the DCOG ALL-10 committee (Figure S1)
   • Cathelijne J.M. Alleman was responsible for the decision tree and sensitivity analyses (Figure 2-4)
   • Raphaële R.L. van Litsenburg and Gertjan J.L Kaspers were involved in clinical data analyses (Table 1-3)
5) Writing the manuscript. The following authors were responsible for writing the manuscript:
- Wing H. Tong, Inge M. van der Sluis, Cathelijne J.M. Alleman, Raphaële R.L. van Litsenburg, Gertjan J.L. Kaspers, Rob Pieters and Carin A. Uyl-de Groot were responsible for writing the manuscript.

6) Contributors Listed in Acknowledgments:
The authors would like to thank all the cooperating pediatric oncology satellite hospitals and the Dutch Childhood Oncology Group (DCOG) for collecting clinical and laboratorial information of the studied children with acute lymphoblastic leukemia. This work was supported by the KiKa® foundation.